Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.45 |
| ▸ | GNPAT | O15228 | 1/20 | 0.43 |
| ▸ | BMP1 | P13497 | 3/20 | 0.40 |
| ▸ | BACE1 | P56817 | 4/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | CASP4 | P49662 | 1/20 | 0.36 |
| ▸ | CASP5 | P51878 | 1/20 | 0.36 |
| ▸ | CASP9 | P55211 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.36 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | CCKBR | P32239 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23133286 | 0.88 | TASP1 (0.43) | TASP1GNPATBMP1BACE1SIRT5 | |
| SCHEMBL23133168 | 0.88 | TASP1 (0.43) | TASP1GNPATBMP1BACE1SIRT5 | |
| SCHEMBL1499722 | 0.88 | TASP1 (0.43) | TASP1GNPATBMP1BACE1SIRT5 | |
| SCHEMBL30173905 | 0.83 | GNPAT (0.49) | GNPATBMP1BACE1SIRT5BACE2 | |
| SCHEMBL30998020 | 0.81 | GNPAT (0.46) | GNPATBACE1CTSD | |
| SCHEMBL24616790 | 0.80 | TASP1 (0.48) | TASP1GNPATBMP1SIRT5PTPN1 | |
| SCHEMBL27857346 | 0.80 | GNPAT (0.53) | GNPATSIRT5CCKBRTSHR | |
| SCHEMBL16494598 | 0.80 | GNPAT (0.53) | GNPATSIRT5CCKBRTSHR | |
| SCHEMBL30168011 | 0.79 | SIRT5 (0.45) | GNPATBMP1BACE1SIRT5CCKBR | |
| SCHEMBL4100803 | 0.77 | CASP1 (0.50) | TASP1GNPATBMP1BACE1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-05-08 | — | — | US | disclosed |
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-04-17 | — | — | US | disclosed |
| US-12139744-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2024-11-12 | — | — | US | disclosed |
| US-12110533-B2 | Stabilisation and isolation of extracellular nucleic acids | QIAGEN GMBH (DE) | 2024-10-08 | — | — | US | disclosed |
| US-20240287574-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2024-08-29 | — | — | US | disclosed |
| EP-4397770-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PreAnalytiX GmbH (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-20240115649-A1 | CASPASE INHIBITION TO ENHANCE REGENERATION AND REPAIR AFTER SKIN OR GUT INJURY AND TO TREAT BACTERIAL OR VIRAL INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-04-11 | — | — | US | disclosed |
| EP-3401406-B1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PREANALYTIX GMBH (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-20230218705-A1 | CASPASE INHIBITORS TO ENHANCE INJURY REPAIR AND TO TREAT BACTERIAL AND VIRAL INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-13 | — | — | US | disclosed |
| EP-4126010-A1 | CASPASE INHIBITORS TO ENHANCE INJURY REPAIR AND TO TREAT BACTERIAL AND VIRAL INFECTIONS | The Johns Hopkins University (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115551536-A | Caspase inhibitors for enhanced wound repair and treatment of bacterial and viral infections | 约翰斯·霍普金斯大学 | 2022-12-30 | — | — | CN | disclosed |
| US-11525155-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2022-12-13 | — | — | US | disclosed |
| US-20220364149-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | TASP1 4313/4885GNPAT 3426/4885BMP1 222/4885 |
| US-12139744-B2 | Stabilisation of biological samples | RNASE1, RNASEH1, EWSR1 | TASP1 4313/4885GNPAT 3426/4885BMP1 222/4885 |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | TASP1 4313/4885GNPAT 3426/4885BMP1 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.